Cargando…
The impact of COVID-19 on familial Mediterranean fever: a nationwide study
The study aimed to evaluate the impact of the coronavirus disease 2019 (COVID-19) in patients with familial Mediterranean fever (FMF) and to assess the relationships between FMF characteristics and severe COVID-19 outcomes such as hospitalization. The study was planned within a national network of 2...
Autores principales: | Günendi, Zafer, Yurdakul, Fatma Gül, Bodur, Hatice, Cengiz, Ahmet Kıvanç, Uçar, Ülkü, Çay, Hasan Fatih, Şen, Nesrin, Keskin, Yaşar, Gürer, Gülcan, Melikoğlu, Meltem Alkan, Altıntaş, Duygu, Deveci, Hülya, Baykul, Merve, Nas, Kemal, Çevik, Remzi, Karahan, Ali Yavuz, Toprak, Murat, Ketenci, Sertaç, Nayimoğlu, Mehmet, Sezer, İlhan, Demir, Ali Nail, Ecesoy, Hilal, Duruöz, Mehmet Tuncay, Yurdakul, Ozan Volkan, Sarıfakıoğlu, Ayşe Banu, Ataman, Şebnem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144686/ https://www.ncbi.nlm.nih.gov/pubmed/34032894 http://dx.doi.org/10.1007/s00296-021-04892-6 |
Ejemplares similares
-
Familial Mediterranean fever: Health-related quality of life and associated variables in a national cohort
por: BODUR, Hatice, et al.
Publicado: (2020) -
Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
por: Ataman, Sebnem, et al.
Publicado: (2021) -
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
por: Çay, H. Fatih, et al.
Publicado: (2022) -
Association of pain and clinical factors on disability and quality of life in systemic sclerosis: A cross-sectional study from Turkish League Against Rheumatism Network
por: Çevik, Remzi, et al.
Publicado: (2022) -
Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs
por: KESKİN, Yaşar, et al.
Publicado: (2020)